Home > Haematology > ASH 2019 > Plenary Scientific Session > HOVON-96: Better outcomes with cyclophosphamide after transplantation

HOVON-96: Better outcomes with cyclophosphamide after transplantation

Presented By
Dr Annoek Broers, Erasmus MC Cancer Institute, the Netherlands
ASH 2019
Following allogeneic haematopoietic stem cell transplantation, cyclophosphamide significantly reduced grades 2 to 4 acute and extensive chronic extensive graft-versus-host disease (GVHD) compared with conventional immunosuppression. Dr Annoek Broers (Erasmus MC Cancer Institute, the Netherlands) presented the study [1]. She noted that GVHD is the major cause of morbidity and mortality after allogeneic haematopoietic stem cell transplantation. Thus, HOVON-96 investigators developed a multicentre, randomised, prospective trial to compare post-transplantation cyclophosphamide with conventional immunosuppression in patients qualifying for allogeneic haematopoietic stem cell transplantation using grafts from HLA-matched siblings and unrelated donors. HOVON-96 randomly assigned 160 patients 1:2 to either conventional immunosuppression with cyclosporine from days -3 to +180 plus mycophenolic acid from days 0 to +84 or post-transplantation cyclophosphamide ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on